CR11444A - Productos quimioterapeuticos cristalinos - Google Patents

Productos quimioterapeuticos cristalinos

Info

Publication number
CR11444A
CR11444A CR11444A CR11444A CR11444A CR 11444 A CR11444 A CR 11444A CR 11444 A CR11444 A CR 11444A CR 11444 A CR11444 A CR 11444A CR 11444 A CR11444 A CR 11444A
Authority
CR
Costa Rica
Prior art keywords
crystal
chemotherapeutic products
chemotherapeutic
products
indazol
Prior art date
Application number
CR11444A
Other languages
English (en)
Inventor
Thomas B Borchardt
Alexandre Chu-Kung
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of CR11444A publication Critical patent/CR11444A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Forma cristalina 2 de N-[4-(3-amino-1H-indazol-4-il)fenil]-N'-(2-fluoro-5-metilfenil)urea que, cuando se mide a aproximadamente 25°C con radiacion a 1,54178
CR11444A 2007-10-19 2010-05-19 Productos quimioterapeuticos cristalinos CR11444A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98126507P 2007-10-19 2007-10-19

Publications (1)

Publication Number Publication Date
CR11444A true CR11444A (es) 2010-10-05

Family

ID=40174735

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11444A CR11444A (es) 2007-10-19 2010-05-19 Productos quimioterapeuticos cristalinos

Country Status (19)

Country Link
US (1) US7772404B2 (es)
EP (1) EP2195299A1 (es)
JP (1) JP2011500708A (es)
KR (1) KR20100084665A (es)
CN (1) CN101827825B (es)
AU (1) AU2008312534A1 (es)
BR (1) BRPI0818337A2 (es)
CA (1) CA2699356A1 (es)
CO (1) CO6270221A2 (es)
CR (1) CR11444A (es)
DO (1) DOP2010000111A (es)
EC (1) ECSP10010175A (es)
GT (1) GT201000099A (es)
MX (1) MX2010004287A (es)
PA (1) PA8800401A1 (es)
RU (1) RU2010119920A (es)
UA (1) UA99490C2 (es)
WO (1) WO2009052231A1 (es)
ZA (1) ZA201002094B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013022801A1 (en) 2011-08-05 2013-02-14 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
CA2818612C (en) 2010-11-19 2020-12-29 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
EP2968113B8 (en) 2013-03-14 2020-10-28 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
MX2017001818A (es) 2014-08-08 2017-05-30 Forsight Vision4 Inc Formulaciones estables y solubles de inhibidores de receptor de quinasa tirosina y metodos de preparacion de los mismos.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7297709B2 (en) * 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
CN1826324B (zh) * 2003-05-22 2011-12-07 雅培制药有限公司 吲唑、苯并异*唑和苯并异噻唑激酶抑制剂
WO2007015569A1 (ja) * 2005-08-01 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を予測する方法
EP1925676A4 (en) * 2005-08-02 2010-11-10 Eisai R&D Man Co Ltd TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR
WO2007076358A1 (en) * 2005-12-23 2007-07-05 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
CA2667720A1 (en) * 2006-11-09 2008-05-15 Abbott Gmbh & Co. Kg. Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor

Also Published As

Publication number Publication date
CN101827825B (zh) 2012-11-21
CA2699356A1 (en) 2009-04-23
ECSP10010175A (es) 2010-06-29
CO6270221A2 (es) 2011-04-20
MX2010004287A (es) 2010-04-30
UA99490C2 (en) 2012-08-27
ZA201002094B (en) 2011-11-30
GT201000099A (es) 2012-03-26
PA8800401A1 (es) 2009-05-15
EP2195299A1 (en) 2010-06-16
AU2008312534A1 (en) 2009-04-23
WO2009052231A1 (en) 2009-04-23
CN101827825A (zh) 2010-09-08
KR20100084665A (ko) 2010-07-27
RU2010119920A (ru) 2011-11-27
US7772404B2 (en) 2010-08-10
DOP2010000111A (es) 2010-07-15
US20090124816A1 (en) 2009-05-14
BRPI0818337A2 (pt) 2017-05-23
JP2011500708A (ja) 2011-01-06

Similar Documents

Publication Publication Date Title
AR116395A2 (es) 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida, su monohidrato o sal en una forma de pureza alta
CL2011000242A1 (es) Uso de compuestos derivados de fenilaminopirimidina para tratar talasemia alfa, delta y anemia celular falciforme, talasemia mayor, talasemia menor, talasemia e-beta o talasemia beta falciforme, o para mejorar o retrasar los sintomas de las mismas y uso de un compuesto especifico para tratar la talasemia.
ECSP109922A (es) Compuestos de pirazol y su uso como inhibidores raf
CR7680A (es) Un nuevo proceso para la sintesis de agomelatina
UY31419A1 (es) Nueva forma cristalina vi de la agomelatina, su procedimiento de preparacion y las composiciones farmacéuticas que la contienen
EA201691119A1 (ru) Производные мочевины или их фармакологически приемлемые соли
BRPI0812222A2 (pt) Compostos ciclobutenodiona substituídos anti-inflamatórios.
NI200900155A (es) COMPUESTOS DE 2-AMINO PIRIMIDINA. Caso: PC 33441A
UA107784C2 (en) Inhibitor of melanin production
CR11463A (es) Compuestos de piridilmetil-sulfonamida
DE602008003911D1 (de) Co-kristalle von propiconazol
UY31229A1 (es) Nuevo procedimiento de sintesis del (7-metoxi-1-naftil)acetonitrilo y aplicacion a la sintesis de la agomelatina
CY1115623T1 (el) Μεθοδος για την συνθεση 7,8-διμεθοξυ-1,3-διϋδρο-2η-3-βενζαζεπιν-2-ονης και εφαρμογη αυτης στη συνθεση της ιβαμπραδινης καθως επισης αλατων προσθηκης αυτης με ενα φαρμακευτικως αποδεκτο οξυ
MX2016017405A (es) Compuestos derivados de 2-(3-piridinil)-1h-benzimidazol y medicamentos que los contienen.
CR11444A (es) Productos quimioterapeuticos cristalinos
CY1111914T1 (el) Μεθοδος συνθεσης της ιβαβραδινης και των αλατων προσθηκης αυτης με ενα φαρμακευτικως αποδεκτο οξυ
HN2011000745A (es) Sales de n-[6-cis-2,6-dimetil-morfolin-4-il)-piridin-3-il]-2-metil-4´-(triflouro-metoxi)-[1,1´-bifenil]-3-carboxamida
MA32834B1 (fr) 3-aminocyclopentanecarboxamides servant de modulateurs de recepteurs de chimiokines
UY32042A (es) Compuestos de 2-aminopirimidina como potentes inhibidores de hsp-90
ES2570463T3 (es) Sulfonamidas para la prevención de la diabetes
CY1117410T1 (el) Κρυσταλλικη μορφη ενος ηλεκτρικου αλατος
CO6280484A2 (es) Forma cristalina 1 de n-[4-(3-amino-1h-indazol-4-il)fenil]-n`-(2-fluoro-5-metilfenil)urea
EA200801366A1 (ru) Производные 3,6-дигидро-2-оксо-6н-1,3,4-тиадиазина
HN2009001437A (es) Nueva procedimiento de obtencion de la forma cristalina v de la agomelatina
CR11386A (es) Productos quimioterapeuticos cristalinos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)